Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 181 AML: Bleximenib or Placebo with Intensive Chemotherapy in KMT2A-rearranged or NPM1-mutant AML
2025-522767-15-00Phase 3Authorised
- Sponsor
- HOVON
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Bleximenib arm with Placebo arm (2 arms). Primary endpoint: Event-free survival (EFS). Planned start Jan 2026; status: authorised.
02
Drugs
bleximenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-522767-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522767-15-00.